This annual award is designed to honor and acknowledge healthcare professionals who are committed to improving outcomes for patients with PAH through excellence in research and clinical practice.
As part of the award, the LA Bio Med will receive a grant in the amount of ,000 to support continued excellence in care for patients with PAH.
Oudiz's achievements made him the obvious and deserved choice." "PAH is still considered a rare disease, impacting less than 200,000 worldwide, and over the last decade, there have been significant advances in diagnosing and treating patients, while continuing to increase awareness of the disease across medical disciplines," said Rino Aldrighetti, president of the Pulmonary Hypertension Association.
The award is supported by an unrestricted educational grant from Actelion and was presented during a reception at the 2011 International Conference of the American Thoracic Society (ATS) in Denver, Colorado."Ron Oudiz has distinguished himself as a researcher dedicated to finding new ways to treat this often fatal disease, as well as a trusted clinician who is passionately committed to helping improve the lives of patients diagnosed with it," said Michael Mc Goon, MD, professor of medicine at the Mayo Clinic College of Medicine and consultant to the Division of Cardiovascular Disease at the Mayo Clinic, chair of the PHA Award Steering Committee."This is an award about excellence in PAH care and Dr.Recent advances  in the understanding of the pathogenic factors leading to the pulmonary vascular disease have led to the development of new therapies targeting specific pathways (the prostacyclin pathway; the endothelin pathway; and the nitric oxide pathway) .The available therapies have effects in PAH, but they do not provide a cure, and in many patients the disease will progress.
The Steering Committee, who selected the recipient, included three physicians and three patients/patient advocates, including: About Pulmonary Arterial Hypertension (PAH)Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual.
The function of the heart and lungs is severely compromised, manifested by a limited exercise capacity, and, ultimately, a reduced life expectancy.